Tech Company Financing Transactions
Ensysce Biosciences Funding Round
Ensysce Biosciences, based in San Diego, received $60 million in investment from Global Emerging Markets.
Transaction Overview
Company Name
Announced On
1/5/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Ensysce will use the funds to progress the clinical development of PF614, a first in class Trypsin Activated Abuse Protection (TAAP) extended-release opioid prodrug, and its Multi-Pill Abuse Resistance (MPAR) overdose protected counterpart, PF614-MPAR.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3210 Merryfield Row
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Ensysce is improving drug efficacy and safety through two unique platforms. These platforms are fundamentally changing the pharmaceutical's industry on how we solve drug delivery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lynn Kirkpatrick
Chief Financial Officer
Regan Lohman
Chief Medical Officer
William Schmidt
Chief Operating Officer
Jeffrey Millard
VP - Bus. Development
Geoff Birkett
VP - Bus. Development
Richard Wright
Browse more venture capital transactions:
Prev: 1/5/2021: AI Clearing venture capital transaction
Next: 1/6/2021: Color Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs